TipRanks
Go Ultimate55% OFF

Tycoon Group Holdings Limited (3390) AI Stock Analysis

HK:3390

Tycoon Group Holdings Limited

(HKEX:3390)

Select Model
Rating:56Neutral
Price Target:HKD 0.25â–²(0.00% Upside)
Action:reiterated
Date:08/06/26

The score is driven primarily by improving financial performance (revenue rebound and a return to positive operating/free cash flow) but held back by thin margins, year-to-year volatility, and rising leverage. Technical signals are weaker (below key moving averages and negative MACD), while valuation is roughly neutral at a moderate P/E with no dividend yield data provided.

Positive Factors
Revenue & Cash RecoveryA clear rebound in 2025 revenue alongside a return to positive operating and free cash flow indicates renewed demand and improved cash generation. Durable cash inflows strengthen liquidity for working capital, inventory funding and debt servicing, enabling reinvestment in distribution capabilities over months.
Negative Factors
Thin ProfitabilityPersistently low and declining margins constrain the company's ability to absorb cost increases or competitive price pressure. With slim operating and net margins, incremental revenue yields little incremental profit, limiting internal financing for growth and leaving returns vulnerable to margin compression over months.

Tycoon Group Holdings Limited (3390) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-10%0%10%20%30%40%HK:3390-12.50%EWH+7.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
HKD 219.03M
Dividend Yield
―
Average Volume (3M)
92.16K
Price to Earnings (P/E)
6.9
Beta (1Y)
0.06
Revenue Growth
13.83%
EPS Growth
―
Country
Hong Kong
Employees
199
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Tycoon Group Holdings Limited Business Overview & Revenue Model

Company Description

Tycoon Group Holdings Limited functions as an investment holding enterprise, specializing in the worldwide distribution and retail of an extensive portfolio of health and wellness products. Its market presence extends across Hong Kong, Mainland China...

How the Company Makes Money

Tycoon Group Holdings Limited makes money primarily by distributing and trading pharmaceutical and healthcare products. Its core revenue model is product sales: the company sources branded and/or generic pharmaceutical products (and potentially other...

Tycoon Group Holdings Limited Financial Statement Overview

Summary

Revenue rebounded in 2025 (+15.3% YoY) and operating/free cash flow turned positive after 2024 outflows, supporting improved fundamentals. Offsetting this, profitability remains thin (net margin ~1.4%, operating margin ~3.6%), gross margin declined versus 2024, and results/cash flows have been volatile across years. Balance sheet leverage is moderate (D/E ~0.80) but has risen since 2023, while ROE is low (~2.9%).

Income Statement

56Neutral

Balance Sheet

62Positive

Cash Flow

54Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.08B1.10B876.04M1.20B1.19B888.87M
Gross Profit252.27M270.04M232.66M321.10M243.53M135.01M
EBITDA75.98M66.46M43.35M356.41M82.89M8.91M
Net Income30.79M15.67M3.24M297.32M43.75M-18.82M
Balance Sheet
Total Assets1.14B1.17B1.01B988.95M1.01B881.46M
Cash, Cash Equivalents and Short-Term Investments22.28M70.34M34.02M39.10M74.60M71.63M
Total Debt410.29M428.05M330.98M206.16M341.60M239.08M
Total Liabilities590.19M625.03M516.61M445.40M718.96M620.20M
Stockholders Equity542.58M537.00M478.85M536.23M293.64M257.92M
Cash Flow
Free Cash Flow23.17M96.47M-78.94M7.97M-64.48M-50.11M
Operating Cash Flow23.21M96.95M-76.62M11.86M-63.03M-42.20M
Investing Cash Flow14.47M-25.10M48.55M45.70M-9.57M-26.25M
Financing Cash Flow-55.13M-35.36M25.62M-92.36M68.25M14.33M

Tycoon Group Holdings Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.24

Price Trends

50DMA0.25Negative
100DMA0.24Negative
200DMA0.27Negative

Market Momentum

MACD-0.00Positive
RSI41.06Neutral
STOCH68.94Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3390, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.25, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.06 is Neutral, neither overbought nor oversold. The STOCH value of 68.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3390.

Tycoon Group Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:3390 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3390HK:339056NeutralHKD 219.03M6.885.70%―13.83%―
HK:0858HK:085854NeutralHKD 147.90M-0.13-154.56%―-7.12%-523.61%
HK:2393HK:239352NeutralHKD 146.77M-1.48-22.16%―-28.07%47.54%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:1110HK:111051NeutralHKD 227.44M16.841.89%8.45%-13.82%112.24%
HK:1518HK:151846NeutralHKD 96.64M-0.60-34.98%11.16%-23.52%-226.85%
HK:1498HK:149842NeutralHKD 123.04M-4.04-21.66%―-6.71%43.14%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%25%HK:3390HK:0858HK:1110HK:1498HK:1518HK:2393Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
HK:3390 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:3390Tycoon Group Holdings Limited0.24-0.04-15.52%
HK:0858Extrawell Pharmaceutical Holdings Limited0.05-0.04-44.57%
HK:1110Kingworld Medicines Group Ltd.0.38-0.16-29.25%
HK:1498PuraPharm Corp. Ltd.0.23-0.19-45.24%
HK:1518New Century Healthcare Holding Co. Ltd.0.20-0.62-75.85%
HK:2393Yestar Healthcare Holdings Co Ltd0.06-0.07-51.54%

Tycoon Group Holdings Limited Corporate Events

Tycoon Group Further Delays Circulars on Key Connected Transactions

Jul 31, 2026

Tycoon Group Holdings Limited has announced a further delay in sending circulars to shareholders regarding proposed revisions of annual caps for continuing connected transactions with JBM Group and Talent Smart Group, as well as the Foci Distribution...

Tycoon Group Delays Key Circulars on Connected Transactions

Jul 10, 2026

Tycoon Group Holdings Limited has announced a delay in sending out two shareholder circulars regarding proposed revisions of annual caps for continuing connected transactions with JBM Group and Talent Smart Group, as well as the Foci Distribution Agr...

Tycoon Group Raises Connected Transaction Caps and Expands JBM Ties

Jun 12, 2026

Tycoon Group Holdings is revising the annual caps for certain continuing connected transactions with JBM Group after reviewing distribution agreements and concluding that transaction volumes are likely to exceed previous projections. The terms of the...

Tycoon Group Raises Caps on Connected Transactions With Talent Smart

Jun 12, 2026

Tycoon Group Holdings Limited plans to raise the annual caps on continuing connected transactions under its 2025 Master Sale and Purchase Agreement with Talent Smart Group after updated procurement plans showed actual transaction values are likely to...

Tycoon Group Wins Strong Shareholder Backing for Capital Mandates at AGM

May 29, 2026

Tycoon Group Holdings Limited reported that all resolutions at its annual general meeting on 29 May 2026 were approved by shareholders via poll, with voting rights attached to the company’s entire issued share capital of 894 million shares and...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026